BioLine Rx (BLRX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

BLRX BioLine Rx

Watchlist

0.278
-0.045-13.97%

Close Nov 22 16:00 ET

0.279
+0.001+0.32%

Post 20:01 ET

23.39MMarket Cap-613P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

12 Health Care Stocks Moving In Thursday's Pre-Market Session
BenzingaNov 21 16:06 ET
BioLineRx Inks Licensing Deal, Share Purchase Agreement
Seeking AlphaNov 21 08:00 ET
BioLineRx And Ayrmid Entered Into A License Agreement For Motixafortide (Commercially Sold In The US As Aphexda), BioLineRx Will Receive A $10M Upfront Payment And Is Also Eligible To Receive Up To An Additional $87M Of Potential Commercial...
BenzingaNov 21 06:33 ET
Express News | BioLine RX Ltd - Transactions to Reduce Biolinerx's Operational Expenses and Debt
ReutersNov 21 06:30 ET
Express News | BioLine RX Ltd - Biolinerx to Receive $10 Mln Upfront, up to $87 Mln in Milestones
ReutersNov 21 06:30 ET
Earnings Preview: BioLine Rx to Report Financial Results Pre-market on November 25
Moomoo NewsNov 20 14:54 ET

Comments

Trytosaveabit

Nov 21 05:35

Hehehe! Here’s the rest!

$BioLine Rx (BLRX.US)$ BioLineRx And Ayrmid Entered Into A License Agreement For Motixafortide (Commercially Sold In The US As Aphexda), BioLineRx Will Receive A $10M Upfront Payment And Is Also Eligible To Receive Up To An Additional $87M Of Potential Commercial Milestones, Plus Royalties Between 18%-23% On Net Sales Of Aphexda
Aphexda is Biolinerx's FDA-Approved Stem Cell Mobilization Agent Indicated In Combination With Filgrastim For Collection And Subsequent Autologous...

Trytosaveabit

Nov 21 05:32

Hmm! News

$BioLine Rx (BLRX.US)$ Reuters· 1 min ago
BioLine RX Ltd - Biolinerx to Receive $10 Mln Upfront, up to $87 Mln in Milestones

13112024

Nov 21 04:03

$BioLine Rx (BLRX.US)$ all leaving, too expensive sell more than $1

Jaguar8

Nov 5 08:02

NEWS

$BioLine Rx (BLRX.US)$
BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024
BioLineRx (NASDAQ: BLRX) announced positive initial results from a Phase 1 clinical trial evaluating motixafortide for stem cell mobilization in sickle cell disease (SCD) gene therapies. The study showed that motixafortide, both alone and combined with natalizumab, was safe...